Krystal Biotech, Inc. KRYS Operating Lease Liability Payments - 2027 (Lessee)

Operating Lease Liability Payments - 2027 (Lessee) at other companies

BridgeBio PharmaBBIO

——

ModernaMRNA

——

Other financials

Income statement

See full

Revenue$116.4M+31.9%

Operating income$53.7M+48.1%

Net income$55.9M+56.5%

EPS (diluted)$1.83+52.5%

Balance sheet

See full

Cash & equivalents$501.3M+62.4%

Total debt$9.1M-5.7%

Total equity$1.3B+29.7%

Total assets$1.4B+30.0%

Cash flow

See full

Operating cash flow$80.4M+160%

CapEx$7.1M+15.2%

Free cash flow$73.2M+196%

Valuation

See full

Market cap$10.26B+45.4%

Enterprise value$9.77B+44.2%

P/E45.6×-11.3×

P/S24.6×+3.4×

Profitability

See full

Operating margin42.8%+10.2pp

Net margin53.9%+16.7pp

FCF margin56.9%+16.5pp

Returns & leverage

See full

Return on equity19.9%+6.0pp

Debt / equity0×0.0×

Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s operating lease liability payments - 2027 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Krystal Biotech, Inc.'s operating lease liability payments - 2027 (lessee)?: Krystal Biotech, Inc. (KRYS) reported operating lease liability payments - 2027 (lessee) of $1.99M in Q1 2026.
How has Krystal Biotech, Inc.'s operating lease liability payments - 2027 (lessee) changed year-over-year?: Krystal Biotech, Inc.'s operating lease liability payments - 2027 (lessee) increased by 1.8% year-over-year, from $1.95M to $1.99M.